Surat Samachar

CAR T-Cell Therapy Market size worth $ 9.62 Billion, Globally, by 2030 at 24.9% CAGR | Emergen Research

 Breaking News
  • No posts were found

CAR T-Cell Therapy Market size worth $ 9.62 Billion, Globally, by 2030 at 24.9% CAGR | Emergen Research

June 29
22:01 2022
CAR T-Cell Therapy Market size worth $ 9.62 Billion, Globally, by 2030 at 24.9% CAGR | Emergen Research
CAR-T cell therapy Market | Emergen Research
Market Size – USD 1.29 Billion in 2021, Market Growth – at a CAGR of 24.9%, Market Trends – Technological advancement in the treatment therapies for cancer

The global CAR T-cells therapy market size reached USD 1.29 Billion in 2021 and is expected to register a revenue CAGR of 24.9% during the forecast period, according to latest analysis by Emergen Research. Increasing prevalence of cancer across the globe and rising mortality rate from cancer are expected to drive the global CAR-T cell therapy market revenue growth over the forecast period. Rapidly expanding clinical trial activities, proliferating mergers & acquisitions, and attractive initial public offerings are contributing to revenue growth of the global CAR T-cell therapy market. Consistent research on cancer and its treatment, as well as advances in medicines, further support the expansion of the market.

Chimeric antigen receptor cell therapy is a technique for altering T-cells, a kind of white blood cell in the laboratory so that they can detect malignant cells. CAR T-cell therapy is often commonly referred to as a type of cell-based gene therapy, as it modifies the genes of T cells to make them more effective at combating cancer. CAR T therapy is used to treat specific types of blood malignancies and is also being investigated for other cancer types. On 28 May 2022 for instance, Novartis announced, that the U.S. Food and Drug Administration (FDA) granted Kymriah, (tisagenlecleucel) accelerated clearance for therapy in patients with refractory follicular lymphoma after two or more lines of systemic therapy. Although the first authorized anti-CD19 CAR T treatment provided promising results, complications such as high relapse rates and resistance were encountered, necessitating the search for modified CAR T-cells that are more effective for therapeutic usage. CAR T-cell structure and manufacturing innovations have resulted in considerable gains in effectiveness and persistence, especially with the creation of fourth-gen CAR T-cells. When used in conjunction with an immune modifier, fourth-generation, and next-generation CAR T-cells will not be restricted by cytotoxic effects and will be an effective weapon for conquering the tumor microenvironment.

Chimeric antigen receptor T-cell treatments have demonstrated the potential to revolutionize cancer therapy, but their use is now restricted to patients with certain recurring and resistant liquid cancers. To understand CAR Ts full potential, investments are being done in optimizing autologous CAR Ts for liquid tumors, expanding number of healthcare settings that administer CAR T, reducing innovation processing times to enable success in solid tumors, and developing next-generation CAR T-cell therapies. CAR T-cell therapies have ample potential as immunotherapy-based cancer treatment. It involves genetically modifying T-cells from the patient or a donor to develop a chimeric antigen receptor that targets a tumor antigen precisely.

Download Sample PDF Copy of this Report to understand structure of the complete report (Including Full TOC, Table & Figures) @ https://www.emergenresearch.com/request-sample/1107

The market intelligence report is a prototype of the 360° overview of the global CAR-T cell therapy industry, shedding light on the estimated market value, share, growth trends, gross revenue, competitive overview, prominent manufacturers and buyers, available product types, and end-use applications.

Competitive Landscape:

The latest research report is inclusive of a precise summary of the intensely competitive landscape of the global CAR-T cell therapy market. It offers a systematic presentation of the company profiles of the leading market players. This section of the report analyzes the effective initiatives undertaken by these players for business expansion in the long run. In addition, this section highlights the key developments and financial positions of these companies to explain the overall market scenario. The company profiles of the established and new players have been assessed using certain effective analytical tools, such as Porter’s Five Forces analysis and SWOT analysis.  

The major companies Covered in the report are: 

Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F.Hoffmann-La Roche Ltd., and Eli Lilly and Company

This report is the latest document discussing the current economic situation gravely impacted by the COVID-19 outbreak in detail. The global health emergency has led to massive changes in the global economy and the CAR-T cell therapy business sphere. The current scenario of this ever-evolving business vertical has been clearly depicted in the report, which contains a broad analysis of the pandemic’s present and future effects.

Segments Covered in this report are:

  • Type Outlook (Revenue, USD Million; 2019-2030)
    • Abecma
    • Breyanzi
    • Kymriah
    • Yescarta
  • Indication Outlook (Revenue, USD Million; 2019-2030)
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Acute Lymphoblastic Leukemia (ALL)
    • Chronic Lymphoblastic Leukemia (CLL)
    • Multiple Myeloma (MM)
    • Follicular Lymphoma (FL)
    • Others
  • End-Use Outlook (Revenue, USD Million; 2019-2030)
    • Hospitals
    • Cancer Treatment Centers

Browse Full Report Description + Research Methodology + Table of Content + [email protected] https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market

Global CAR-T cell therapy Market Highlights:

  • The diffuse large B-cell lymphoma segment accounted for rapid revenue share in 2021. Diffuse large B-cell lymphoma is a fast-growing cancer of the lymphatic system, a vital immune system component. It affects blood cells that produce antibodies to fight against infections. DLBCL is curable in some cases. The majority of DLBCL patients respond favorably to first therapies such as chemotherapy. For some individuals, the illness becomes resistant, in the sense that it no longer responds to treatment, or it relapses, in the sense that it returns after treatment. These patients could be treated with chimeric antigen receptor T-cell therapy, which employs body’s own immune cells to battle DLBCL. T-cells are removed from the patient’s blood, modified in the lab with so-called chimeric antigen receptors that assist in recognizing and destroying cancer cells, and then reintroduced into the patient’s blood.
  • The hospital segment accounted for moderate revenue share in 2021. The CAR T-cell therapy reprograms the subject’s T-cells to target tumor antigens. CAR T-cell therapy has shown full remission rates of 80 to 90% in younger patients with B-cell acute lymphoblastic leukemia and 40% in patients with symptomatic B-cell non-Hodgkin lymphomas who have failed several prior lines of therapy.
  • The multiple myeloma segment accounted for a significant revenue share in 2021. CAR T-cell therapy is a promising treatment for people with relapsed or refractory multiple myeloma who have not responded to prior medications. It is a highly specialized treatment that involves genetically modifying a patient’s T cells in order to eliminate their multiple myeloma by targeting B-cell maturation antigen (BCMA).
  • The market in Europe accounted for moderate revenue share in 2021. T-cell therapy employing chimeric antigen receptors is one of Europe’s most promising cancer medicines. The Committee for Advanced Therapies and the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion proposing the granting of marketing approval for the medicinal product Kymriah for pediatric and young adult patients up to 25 years of age who have B cell acute lymphoblastic leukemia that is refractory, in relapse after transplant, or even in a second or later relapse, and for adult patients. Such approvals are contributing to revenue growth of the market.

Key Parameters Analyzed in This Section:

  • Company Profiles
  • Gross Revenue
  • Profit margins
  • Product sales trends
  • Product pricing
  • Industry Analysis
  • Sales & distribution channels

Regional Segmentation:

  • North America
  • Latin America
  • Europe
  • Middle East & Africa
  • Asia Pacific

Key Points Covered in This Section: 

  • Regional contribution
  • Estimated revenue generation
  • Vital data and information about the consumption rate in all the leading regional segments
  • An expected rise in market share
  • Forecast growth in the overall consumption rate

Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/1107

Target Audience of the Report:

  • Leading Companies
  • Large, medium-sized, and small enterprises
  • Investors
  • Value-Added Resellers (VARs)
  • Venture capitalists
  • Third-party knowledge providers

Key Offerings of the Report:

  • Detailed overview of market dynamics including drivers, restraints, opportunities, challenges, and growth prospects
  • Analysis of the key strategic initiatives and competitive landscape including mergers & acquisitions, joint ventures, collaborations, product launches, and brand promotions, and partnerships, among others
  • Comprehensive analysis of the industry outlook and analysis of the industrial chain
  • Market forecast based on global, regional, and country-level market analysis
  • Competitive landscape benchmarking
  • In-depth analysis of the key market players with their product portfolios, financial positions, unique selling points, market share and size, and a comprehensive overview of their business

Buy Your Copy now @ https://www.emergenresearch.com/select-license/1107

Thank you for reading our report. If you have any requests for customization of the latest report, kindly get in touch with us. Our team will assist you and ensure the report is designed as per your requirements.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trend’s existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Media Contact
Company Name: Emergen Research
Contact Person: Eric Lee
Email: Send Email
Phone: +1 (604) 757-9756
Address:14671 110 Avenue Surrey, British Columbia, V3R2A9
City: Surrey
State: British Columbia
Country: Canada
Website: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market

Related Articles